Time to rethink our approach to the Pharmaceutical Benefits Scheme (PBS) listing of medicines: the case of pregabalin
Karl Winckel A B , Mark Daglish C D , David Pache B E and Samantha A. Hollingworth
B F
+ Author Affiliations
- Author Affiliations
A Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Qld 4102, Australia.
B School of Pharmacy, University of Queensland, 20 Cornwall Street, Woolloongabba, Qld 4102, Australia. Email: kwinckel@pharmacy.uq.edu.au; d.pache@uq.edu.au
C Metro North Hospital and Health Service, Herston, Qld 4029, Australia. Email: Mark.Daglish@health.qld.gov.au
D Faculty of Medicine, University of Queensland, Herston, Qld 4006, Australia.
E Mater Hospital, Raymond Terrace, South Brisbane, Qld 4101, Australia.
F Corresponding author. Email: s.hollingworth@uq.edu.au
Australian Health Review 45(2) 261-262 https://doi.org/10.1071/AH20060
Submitted: 6 April 2020 Accepted: 14 April 2020 Published: 3 September 2020
References
[1] Pharmaceutical Benefits Advisory Committee. Pregabalin, capsule, 25 mg, 75 mg, 150 mg and 300 mg, Lyrica® – March 2011. 2011. Available at: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-03/pbac-psd-pregabalin-march11 [verified 28 February 2020].[2] Pharmaceutical Benefits Advisory Committee. Pregabalin, capsules, 25 mg, 75 mg, 150 mg and 300 mg, Lyrica® – March 2012. 2012. Available at: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-03/pregabalin [verified 28 February 2020].
[3] Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010; 49 661–9.
| A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.Crossref | GoogleScholarGoogle Scholar | 20818832PubMed |
[4] Savelloni J, Gunter H, Lee KC, Hsu C, Yi C, Edmonds KP, Furnish T, Atayee RS. Risk of respiratory depression with opioids and concomitant gabapentinoids. J Pain Res 2017; 10 2635–41.
| Risk of respiratory depression with opioids and concomitant gabapentinoids.Crossref | GoogleScholarGoogle Scholar | 29180889PubMed |
[5] Crossin R, Scott D, Arunogiri S, Smith K, Dietze PM, Lubman DI. Pregabalin misuse-related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances. Med J Aust 2019; 210 75–9.
| Pregabalin misuse-related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances.Crossref | GoogleScholarGoogle Scholar | 30712302PubMed |
[6] Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med 2017; 14 e1002396
| Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study.Crossref | GoogleScholarGoogle Scholar | 28972983PubMed |
[7] Nahar LK, Murphy KG, Paterson S. Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study. J Anal Toxicol 2019; 43 564–70.
| Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study.Crossref | GoogleScholarGoogle Scholar | 31062862PubMed |
[8] Harvey KJ, Day RO, Campbell WG, Lipworth W. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? Med J Aust 2011; 194 567–8.
| Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?Crossref | GoogleScholarGoogle Scholar | 21644867PubMed |
[9] Karnon J, Edney L, Sorich M. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme. Aust Health Rev 2017; 41 1–6.
| Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.Crossref | GoogleScholarGoogle Scholar | 26954612PubMed |
